CNTNAP2
Contactin-associated protein-like 2
Also known as: Caspr2, CNTP2_HUMAN, KIAA0868, NRXN4
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UHC6
- Gene
- CNTNAP2
- Ensembl
- ENSG00000174469
- Chromosome
- 7
- Canonical length
- 1331 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
OverviewNCBI Gene
This gene encodes a member of the neurexin family which functions in the vertebrate nervous system as cell adhesion molecules and receptors. This protein, like other neurexin proteins, contains epidermal growth factor repeats and laminin G domains. In addition, it includes an F5/8 type C domain, discoidin/neuropilin- and fibrinogen-like domains, thrombospondin N-terminal-like domains and a putative PDZ binding site. This protein is localized at the juxtaparanodes of myelinated axons, and mediates interactions between neurons and glia during nervous system development and is also involved in localization of potassium channels within differentiating axons. This gene encompasses almost 1.5% of chromosome 7 and is one of the largest genes in the human genome. It is directly bound and regulated by forkhead box protein P2, a transcription factor related to speech and language development. This gene has been implicated in multiple neurodevelopmental disorders, including Gilles de la Tourette syndrome, schizophrenia, epilepsy, autism, ADHD and intellectual disability. [provided by RefSeq, Jul 2017]
Canonical amino-acid sequenceUniProt
1331 residues, UniProt reviewed canonical sequence.
>Q9UHC6|CNTNAP2
1 MQAAPRAGCG AALLLWIVSS CLCRAWTAPS TSQKCDEPLV SGLPHVAFSS SSSISGSYSP
61 GYAKINKRGG AGGWSPSDSD HYQWLQVDFG NRKQISAIAT QGRYSSSDWV TQYRMLYSDT
121 GRNWKPYHQD GNIWAFPGNI NSDGVVRHEL QHPIIARYVR IVPLDWNGEG RIGLRIEVYG
181 CSYWADVINF DGHVVLPYRF RNKKMKTLKD VIALNFKTSE SEGVILHGEG QQGDYITLEL
241 KKAKLVLSLN LGSNQLGPIY GHTSVMTGSL LDDHHWHSVV IERQGRSINL TLDRSMQHFR
301 TNGEFDYLDL DYEITFGGIP FSGKPSSSSR KNFKGCMESI NYNGVNITDL ARRKKLEPSN
361 VGNLSFSCVE PYTVPVFFNA TSYLEVPGRL NQDLFSVSFQ FRTWNPNGLL VFSHFADNLG
421 NVEIDLTESK VGVHINITQT KMSQIDISSG SGLNDGQWHE VRFLAKENFA ILTIDGDEAS
481 AVRTNSPLQV KTGEKYFFGG FLNQMNNSSH SVLQPSFQGC MQLIQVDDQL VNLYEVAQRK
541 PGSFANVSID MCAIIDRCVP NHCEHGGKCS QTWDSFKCTC DETGYSGATC HNSIYEPSCE
601 AYKHLGQTSN YYWIDPDGSG PLGPLKVYCN MTEDKVWTIV SHDLQMQTPV VGYNPEKYSV
661 TQLVYSASMD QISAITDSAE YCEQYVSYFC KMSRLLNTPD GSPYTWWVGK ANEKHYYWGG
721 SGPGIQKCAC GIERNCTDPK YYCNCDADYK QWRKDAGFLS YKDHLPVSQV VVGDTDRQGS
781 EAKLSVGPLR CQGDRNYWNA ASFPNPSSYL HFSTFQGETS ADISFYFKTL TPWGVFLENM
841 GKEDFIKLEL KSATEVSFSF DVGNGPVEIV VRSPTPLNDD QWHRVTAERN VKQASLQVDR
901 LPQQIRKAPT EGHTRLELYS QLFVGGAGGQ QGFLGCIRSL RMNGVTLDLE ERAKVTSGFI
961 SGCSGHCTSY GTNCENGGKC LERYHGYSCD CSNTAYDGTF CNKDVGAFFE EGMWLRYNFQ
1021 APATNARDSS SRVDNAPDQQ NSHPDLAQEE IRFSFSTTKA PCILLYISSF TTDFLAVLVK
1081 PTGSLQIRYN LGGTREPYNI DVDHRNMANG QPHSVNITRH EKTIFLKLDH YPSVSYHLPS
1141 SSDTLFNSPK SLFLGKVIET GKIDQEIHKY NTPGFTGCLS RVQFNQIAPL KAALRQTNAS
1201 AHVHIQGELV ESNCGASPLT LSPMSSATDP WHLDHLDSAS ADFPYNPGQG QAIRNGVNRN
1261 SAIIGGVIAV VIFTILCTLV FLIRYMFRHK GTYHTNEAKG AESAESADAA IMNNDPNFTE
1321 TIDESKKEWL ILocalizationUniProt · AlphaFold · HPA
Whether an antibody against CNTNAP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 35 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 35 nTPM
- spinal cord: 32 nTPM
- amygdala: 19 nTPM
- hypothalamus: 17 nTPM
- midbrain: 17 nTPM
- hippocampal formation: 14 nTPM
Single-cell type
- brain inhibitory neurons: 4,144 nCPM
- brain excitatory neurons: 3,027 nCPM
- other brain neurons: 2,546 nCPM
- prostatic glandular cells: 1,369 nCPM
- retinal ganglion cells: 1,325 nCPM
- retinal amacrine cells: 1,233 nCPM
Immune cell
- naive B-cell: 2.5 nTPM
- memory B-cell: 0.7 nTPM
- total PBMC: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- cerebral cortex: 126 nTPM
- basal ganglia: 95 nTPM
- pons: 81 nTPM
- thalamus: 78 nTPM
- white matter: 74 nTPM
- hypothalamus: 73 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about CNTNAP2.
Disease | AllUniProt
Conditions CNTNAP2 is implicated in, by any mechanism.
- Autism 15 (AUTS15) MIM:612100
- Pitt-Hopkins-like syndrome 1 (PTHSL1) MIM:610042
Disease | GeneticClinVar
112 pathogenic / likely-pathogenic of 1,956 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Cortical dysplasia-focal epilepsy syndrome
- Inborn genetic diseases
- Autism, susceptibility to, 15
- See cases
- Autism spectrum disorder
Disease | AutoantibodyPubMed
Conditions in which antibodies against CNTNAP2 are reported. Each links to that disease's full target list.
- Encephalitis 59
- Hashimoto Disease 32
- Limbic Encephalitis 32
- Autoimmune Diseases of the Nervous System 23
- Epilepsy 12
- Seizures 11
- Thymoma 9
- Brain Diseases 8
- Thymus Neoplasms 8
- Pain 7
- Neoplasm Recurrence, Local 6
- Paraneoplastic Syndromes, Nervous System 6
- Peripheral Nervous System Diseases 5
- Guillain-Barre Syndrome 4
- Myasthenia Gravis 4
- Ataxia 3
- Cerebellar Ataxia 3
- Lung Neoplasms 3
Showing 18 of 30 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for CNTNAP2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
198 publications
- Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.
2010 · Lancet Neurol · RCR 21.9 · 778 citations - The clinical spectrum of Caspr2 antibody-associated disease.
2016 · Neurology · RCR 13.4 · 319 citations - Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients.
2017 · Ann Neurol · RCR 12.2 · 270 citations - Immune-mediated neurological syndromes in SARS-CoV-2-infected patients.
2021 · J Neurol · RCR 10 · 151 citations - Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia.
2011 · Ann Neurol · RCR 9.9 · 334 citations
Show 20 more of 198 total
- The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis.
2017 · Nat Rev Neurol · RCR 8.3 · 202 citations - Magnetic Resonance Imaging Characteristics of LGI1-Antibody and CASPR2-Antibody Encephalitis.
2024 · JAMA Neurol · RCR 8.3 · 37 citations - Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy.
2020 · Ann Neurol · RCR 7.7 · 122 citations - LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.
2018 · J Neurol Neurosurg Psychiatry · RCR 7.3 · 162 citations - Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations.
2022 · Mayo Clin Proc · RCR 6.3 · 57 citations - Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures.
2016 · JAMA Neurol · RCR 6.2 · 145 citations - Immune or Genetic-Mediated Disruption of CASPR2 Causes Pain Hypersensitivity Due to Enhanced Primary Afferent Excitability.
2018 · Neuron · RCR 6.1 · 148 citations - Ultrahigh frequencies of peripherally matured LGI1- and CASPR2-reactive B cells characterize the cerebrospinal fluid in autoimmune encephalitis.
2024 · Proc Natl Acad Sci U S A · RCR 5.8 · 36 citations - Distinct HLA associations of LGI1 and CASPR2-antibody diseases.
2018 · Brain · RCR 5.6 · 134 citations - Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies.
2017 · J Neurol Neurosurg Psychiatry · RCR 5.5 · 114 citations - Systematic review of the clinical spectrum of CASPR2 antibody syndrome.
2020 · J Neurol · RCR 5.3 · 78 citations - The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
2016 · Neurology · RCR 5.3 · 122 citations - Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome.
2017 · Eur J Neurol · RCR 5.2 · 116 citations - Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.
2013 · JAMA Neurol · RCR 5.1 · 148 citations - Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis.
2023 · Brain · RCR 4.7 · 32 citations - Chronic pain as a manifestation of potassium channel-complex autoimmunity.
2012 · Neurology · RCR 4.5 · 138 citations - Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features.
2020 · J Neurol Neurosurg Psychiatry · RCR 4.5 · 78 citations - Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.
2018 · Ann Neurol · RCR 4.2 · 95 citations - Leucine-Rich Glioma-Inactivated 1 versus Contactin-Associated Protein-like 2 Antibody Neuropathic Pain: Clinical and Biological Comparisons.
2021 · Ann Neurol · RCR 3.8 · 53 citations - Immunotherapy-Resistant Neuropathic Pain and Fatigue Predict Quality-of-Life in Contactin-Associated Protein-Like 2 Antibody Disease.
2025 · Ann Neurol · RCR 3.8 · 10 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.55
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.29
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adult behavior
- brain development
- cell adhesion
- cell population proliferation
- cerebral cortex development
- clustering of voltage-gated potassium channels
- learning
- limbic system development
- neuron projection development
- neuron projection morphogenesis
- neuron recognition
- positive regulation of gap junction assembly
- prepulse inhibition
- protein localization to juxtaparanode region of axon
- social behavior
- striatum development
- superior temporal gyrus development
- thalamus development
- transmission of nerve impulse
- vocal learning
- vocalization behavior
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Coagulation factor 5/8, C-terminal domain
- EGF-like domain
- Laminin G domain
- Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain
- Neurexin/syndecan/glycophorin C
- Galactose-binding-like domain superfamily
- Concanavalin A-like lectin/glucanase domain superfamily
- Fibrinogen-like, C-terminal
- Neurexin-related cell adhesion and synaptic protein
- F5/8 type C domain
- Laminin G domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CNTNAP2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CNTNAP2 as an antibody target. Whether an autoantibody or antibody against CNTNAP2 could matter depends on whether native CNTNAP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CNTNAP2 is annotated at the cell surface, where native CNTNAP2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label CNTNAP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...